175 related articles for article (PubMed ID: 32311194)
41. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
[TBL] [Abstract][Full Text] [Related]
42. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
Théberge I; Vandal N; Guertin MH; Perron L
Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
[TBL] [Abstract][Full Text] [Related]
43. BreastScreen-based mammography screening in women with a personal history of breast cancer, Western Australian study.
Houssami N; Tresham JJ; Fritschi L; Wylie LE
Med J Aust; 2011 Oct; 195(8):460-4. PubMed ID: 22004397
[TBL] [Abstract][Full Text] [Related]
44. [Pathological characteristics in screening versus clinically-detected breast cancer].
Paziault M; Terrade FX; Fermeaux V; Pascal B; Darreye G; Dussartre C; Gilquin M; Labrousse F; Tubiana-Mathieu N
Bull Cancer; 2006 Jul; 93(7):731-6. PubMed ID: 16873082
[TBL] [Abstract][Full Text] [Related]
45. Balancing sensitivity and specificity: sixteen year's of experience from the mammography screening programme in Copenhagen, Denmark.
Utzon-Frank N; Vejborg I; von Euler-Chelpin M; Lynge E
Cancer Epidemiol; 2011 Oct; 35(5):393-8. PubMed ID: 21239242
[TBL] [Abstract][Full Text] [Related]
46. Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer.
Saxby K; Nickson C; Mann GB; Park A; Bromley H; Velentzis L; Procopio P; Canfell K; Petrie D
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):847-857. PubMed ID: 33253057
[No Abstract] [Full Text] [Related]
47. Breast carcinoma in situ: risk factors and screening patterns.
Claus EB; Stowe M; Carter D
J Natl Cancer Inst; 2001 Dec; 93(23):1811-7. PubMed ID: 11734598
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
49. Budget impact analysis of switching to digital mammography in a population-based breast cancer screening program: a discrete event simulation model.
Comas M; Arrospide A; Mar J; Sala M; Vilaprinyó E; Hernández C; Cots F; Martínez J; Castells X
PLoS One; 2014; 9(5):e97459. PubMed ID: 24832200
[TBL] [Abstract][Full Text] [Related]
50. Triple-negative breast cancer in West Virginia.
Abraham J; Flanagan M; Hazard H; Jubelirer S; Tirona MT; Vona-Davis L
W V Med J; 2009 Oct; 105 Spec No():54-9. PubMed ID: 19999267
[TBL] [Abstract][Full Text] [Related]
51. Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?
Daroles J; Borget I; Suciu V; Mazouni C; Delaloge S; Balleyguier C
Eur J Cancer; 2017 Nov; 85():23-30. PubMed ID: 28881248
[TBL] [Abstract][Full Text] [Related]
52. Long-term out of pocket expenditure of people with cancer: comparing health service cost and use for indigenous and non-indigenous people with cancer in Australia.
Callander E; Bates N; Lindsay D; Larkins S; Topp SM; Cunningham J; Sabesan S; Garvey G
Int J Equity Health; 2019 Feb; 18(1):32. PubMed ID: 30755217
[TBL] [Abstract][Full Text] [Related]
53. Comparison of breast cancers detected in the Verona screening program following transition to digital breast tomosynthesis screening with cancers detected at digital mammography screening.
Caumo F; Romanucci G; Hunter K; Zorzi M; Brunelli S; Macaskill P; Houssami N
Breast Cancer Res Treat; 2018 Jul; 170(2):391-397. PubMed ID: 29557996
[TBL] [Abstract][Full Text] [Related]
54. Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
Sihto H; Lundin J; Lehtimäki T; Sarlomo-Rikala M; Bützow R; Holli K; Sailas L; Kataja V; Lundin M; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
Clin Cancer Res; 2008 Jul; 14(13):4103-10. PubMed ID: 18593987
[TBL] [Abstract][Full Text] [Related]
55. National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year.
Ong MS; Mandl KD
Health Aff (Millwood); 2015 Apr; 34(4):576-83. PubMed ID: 25847639
[TBL] [Abstract][Full Text] [Related]
56. The patient burden of screening mammography recall.
Alcusky M; Philpotts L; Bonafede M; Clarke J; Skoufalos A
J Womens Health (Larchmt); 2014 Sep; 23 Suppl 1():S11-9. PubMed ID: 25247382
[TBL] [Abstract][Full Text] [Related]
57. MRI of the breast as part of the assessment in population-based mammography screening.
Bick U; Engelken F; Diederichs G; Dzyuballa R; Ortmann M; Fallenberg EM
Rofo; 2013 Sep; 185(9):849-56. PubMed ID: 23740312
[TBL] [Abstract][Full Text] [Related]
58. Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer.
Choi SH; Choi JS; Han BK; Ko EY; Ko ES; Park KW
Radiology; 2019 Jul; 292(1):37-48. PubMed ID: 31038406
[TBL] [Abstract][Full Text] [Related]
59. Treatment Intensity Differences After Early-Stage Breast Cancer (ESBC) Diagnosis Depending on Participation in a Screening Program.
Elder K; Nickson C; Pattanasri M; Cooke S; Machalek D; Rose A; Mou A; Collins JP; Park A; De Boer R; Phillips C; Pridmore V; Farrugia H; Bruce Mann G
Ann Surg Oncol; 2018 Sep; 25(9):2563-2572. PubMed ID: 29717421
[TBL] [Abstract][Full Text] [Related]
60. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]